Loading
Lung Cancer Research Studies / Histone Deacetylase Inhibitors Research / Advanced Breast Cancer Therapies · Journal article
Journal of Clinical Investigation · August 18, 2026
Raises a question worth testing. It does not answer one.
This preclinical study demonstrates using genetically engineered mouse models that EED, a core PRC2 scaffolding subunit, supports SCLC neuroendocrine identity and is required for LUAD-to-SCLC transformation. EED inactivation impairs SCLC tumorigenesis and redirects tumors toward LUAD histology through derepression of bivalently marked oncogenic signaling genes, suggesting a potential therapeutic target in therapy-induced transformation.
Preclinical mechanistic study using CRISPR-based autochthonous immunocompetent GEMMs and human patient-derived xenografts. Autochthonous immunocompetent genetically engineered mouse models with SCLC or EGFR-mutant LUAD with Rb1/Trp53 inactivation; human SCLC patient-derived xenografts. Intervention: CRISPR-based inactivation of EED (PRC2 scaffolding subunit) at tumor initiation. Compared with: Control tumors with intact EED and PRC2 complex expression.
EED inactivation impaired SCLC tumorigenesis and promoted LUAD histological identity through NEUROD1-positive intermediate state EED loss derepressed bivalent genes marked by H3K27me3 and H3K4me3, including RAS, PI3K, and MAPK pathway genes and NEUROD1 In EGFR-mutant LUAD GEMM with Rb1/Trp53 inactivation, EED inactivation prevented SCLC emergence after EGFR withdrawal and redirected tumors toward mucinous LUAD with reduced metastasis
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These findings nominate EED as a therapeutic target for investigation in patients with therapy-associated LUAD-to-SCLC transformation, but clinical translation requires validation in human studies and drug development.
Mechanistic study in genetically engineered mouse models identifying EED as a regulator of SCLC identity and LUAD-to-SCLC transformation; lacks clinical trial data or human validation beyond xenograft correlation.
As stated by the source record.
These findings nominate EED as a therapeutic target for investigation in patients with therapy-associated LUAD-to-SCLC transformation, but clinical translation requires validation in human studies and drug development.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Lung cancer histological subtypes include lung adenocarcinoma (LUAD) and small cell lung cancer (SCLC). Although usually distinct, rare combined LUAD/SCLC tumors occur, and LUAD can transform into SCLC as a mechanism of resistance to targeted therapies, particularly in EGFR -Mutant LUADs with RB1/TP53 inactivation. Although PRC2 complex expression increases during this transformation, its functional role remains unclear. Using CRISPR-based autochthonous immunocompetent GEMMs, we found that inactivation of EED, the core PRC2 scaffolding subunit, impaired SCLC tumorigenesis and promoted LUAD histological identity likely through a NEUROD1-positive intermediate state. Mechanistically, EED loss derepressed bivalent genes co-marked by H3K27me3 and H3K4me3, including LUAD oncogenic RAS, PI3K, and MAPK pathway genes and NEUROD1. These same LUAD oncogenic signaling genes were bivalently repressed in human SCLC patient-derived xenografts, suggesting a conserved PRC2-dependent mechanism that represses LUAD oncogenic signaling and thereby supports the SCLC neuroendocrine identity. In a complementary EGFR -Mutant LUAD GEMM with Rb1 and Trp53 inactivation, EED inactivation at tumor initiation prevented the emergence of SCLC histology after EGFR oncogene withdrawal and redirected recurrent tumors toward mucinous LUAD states with reduced spontaneous metastasis. These findings identify PRC2/EED as a regulator of SCLC neuroendocrine identity and nominate pharmacologic EED inhibition for future investigation in therapy-associated LUAD-to-SCLC transformation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.